[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condbio:diffuse-large-b-cell-lymphoma:cd22-gene":3},{"condition":4,"biomarker":5,"total":6,"trials":7},"Diffuse Large B-Cell Lymphoma","CD22 Gene",4,[8,16,23,30],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT05098613","Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R\u002FR B-NHL Patients",[12],"Phase 1","RECRUITING","2026-08-26T02:16:59.895916Z","2026-07-19T19:36:05.125264Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT05442515","CD19\u002FCD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies",[20],"Phase 1\u002FPhase 2","2026-08-26T02:18:21.216897Z","2026-07-05T05:32:16.802455Z",{"nct_id":24,"title":25,"phases":26,"status":27,"updated_at":28,"content_modified":29},"NCT03226704","Leukapheresis for CAR or Adoptive Cell Therapy Manufacturing",[],"ENROLLING_BY_INVITATION","2026-08-26T02:19:13.549512Z","2026-06-16T05:54:07.964568Z",{"nct_id":31,"title":32,"phases":33,"status":27,"updated_at":34,"content_modified":35},"NCT07168486","CD19.20.22 CAR T-cells for Patients With Relapsed\u002FRefractory B-Cell Lymphomas",[12],"2026-08-26T02:19:19.975067Z","2026-06-16T05:54:07.870155Z"]